Role of endothelial cell dysfunction in essential hypertension

Journal of Association of Physicians of India

Volumn 52, Issue DEC, 2004, Pages 966-969

  Sainani, G S ^a   Maru, Vibhuti G ^a  

^a JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; NITRIC OXIDE; PROSTACYCLIN; THROMBOXANE A2;

ARTICLE; BLOOD; CASE CONTROL STUDY; ENZYME IMMUNOASSAY; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

CASE-CONTROL STUDIES; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; HUMANS; HYPERTENSION; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NITRIC OXIDE; THROMBOXANE A2;

EID: 20344369051     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Kobayashi M, Uesugi S. The role of hypertension as risk for atherosclerosis. Rinsho Byori (JAPAN) 1995;43:104 -10.
2. Somova L, Mufunda J. Renin-angiotensin-aldosterone system and thromboxane A2/prostacyclin in normotensive and hypertensive black Zimbabweans (Abstract). Ethn Dis 1992;2:27-34.
3. Yuan SJ, et al. Plasma nitric oxide levels in newborn infants with sepsis. J Pediatrics 1993;123:435-38.
4. Amroso A, Cossu MF, Mariotti A, Guido F, Ferri GM, De Rosa FG, Sportelli G. Increased plasma levels of endothelin in patients with essential arterial hypertension. Riv Eur Sci Med Farmacol 1996;18:33-37.
5. Zoccali C, Leonardis D, Parlongo S, Mallamaci F, Postorino M.Urinary and plasma endothelin 1 in essential hypertension and in hypertension secondary to renoparenchymal disease. Nephrol Dial Transplant 1995;10:1320-23.
6. Hlubocka Z, Umnerova V, Heller S, Peleska J, Jindra A, Jachymova M, Kvasnicka J, Aschermann M, Horky K. Is mild essential hypertension without obvious organ complications and risk factors associated with increased levels of circulating markers of endothelial dysfunction? Effect of ACE inhibitor therapy. Vnitr Lek 2002;48:718-23.
7. Davenport A, Ashby M, Easton P, Ella S, Bedford J, Dickerson C, Nunez D, Capper S, Brown M. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: comparison of levels in patients with essential hypertension and normotensive control subjects. Clin Sci (Lond) 1990;78:261-64.
8. Veglio F, Bertello P, Pinna G, Mulatero P, Rossi A, Gurioli L, Panarelli M, Chiandussi L. Plasma endothelin in essential hypertension and diabetes mellitus. J Hum Hypertens 1993;7:321-25.
9. Hoffman A, Grossman E, Goldstein D, Gill J Jr, Keiser H. Urinary excretion rate of endothelin-1 in patients with essential hypertension and salt sensitivity. Kidney Int 1994;45:556-60.
10. Taddei S, Virdis A, Ghiadoni L, Sudano I, Notari M, Salvetti A. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation 1999;100:1680-83.
11. Taddei S, Virdis A, Ghiadoni L, Sudano I, Magagna A, Salvetti A. Role of endothelin in the control of peripheral vascular tone in human hypertension. Heart Fail Rev 2001;6:277-85.
12. Cockcroft J, Chowienczyk P, Benjamin N, Ritter J. Preserved endothelium-dependent vasodilation in patients with essential hypertension. N Engl J Med 1994;330:1036-40.
13. Node K, Kitakaze M, Yoshikawa H, Kosaka H, Hori M. Reduced Plasma Concentrations of Nitrogen Oxide in Individuals With Essential Hypertension. Hypertension 1997;30:405-10.
14. Kumar K, Das U. Are free radicals involved in the pathobiology of human essential hypertension? Free Radic Res Commun 1993;19:59-66.
15. Moriel P, Sevanian A, Ajzen A, Zanella M, Plavnik F, Rubbo H, Abdalla P. Nitric oxide, cholesterol oxides and endotheliumdependent vasodilation in plasma of patients with essential hypertension. Braz J Med Biol Res 2002;35:1301-09.
16. Zhao W, Richardson J. Prostacyclin, thromboxane A2, and hypertension. Clin Invest Med 1990;13:343-52.
17. Frolich J. Prostacyclin in hypertension. Z Kardiol 1992;81:303-9.
18. Uehara Y, Ishii M, Ikeda T, Atarashi K, Takeda T, Murao S.Plasma levels of 6-keto-prostaglandin F1 alpha in normotensive subjects and patients with essential hypertension. Prostaglandins Leukot Med 1983;11:95-104.
19. Chen LS, Ito T, Ogawa K, Shikano M, Satake T. Plasma concentrations of 6-keto-prostaglandin F1 alpha, thromboxane B2 and platelet aggregation in patients with essential hypertension. Jpn Heart J 1984;25:1001-9.
20. Uyama O, Nagatsuka K, Nakamura M, Matsumoto M, Fujisawa A, Yoneda S, Kimura K, Abe H. Plasma concentrations of 6-keto-prostaglandin F1 alpha in patients with hypertension, cerebrovascular disease or Takayasu's arteritis. Thromb Res 1982;25:71-79.